How researchers are using the Maxpar Direct Immune Profiling Assay
Fluidigm CyTOF® technology and the Maxpar® Direct™ Immune Profiling Assay™ provide best-in-class immune monitoring with the cost, flexibility and consistency needed for standardized immune monitoring.
Look through the publications, preprints and clinical trials listed below to see the number of ways that researchers are using the assay to advance their studies of COVID-19 and other diseases and conditions.
Presenter: Frederik De Smet, MSc, PhD Assistant Professor, University of Leuven
Read the Spotlight article on Benjamin Terrier, lead author of this publication, to see how his lab used this immune profiling assay to define a distinct immune response phenotype in severe and critically ill COVID-19 patients that could help identify high-risk individuals.
"Analyzing the immune response of patients … by mass cytometry allows us to cover the innate and adaptive immune responses simultaneously. Not only could we analyze immune cells, but also cytokine production and the transcriptional signatures in these patients. Essentially, we could look at everything in the whole blood.”
— Benjamin Terrier, MD, PhD, University of Paris
‘High-dimensional single-cell analysis reveals the immune characteristics of COVID-19’
Shi, W. et al. American Journal of Physiology: Lung Cellular and Molecular Physiology (2020): doi:10.1152/ajplung.00355.2020.
‘A streamlined CyTOF workflow to facilitate standardized multi-site immune profiling of COVID-19 patients’
Geanon, D. et al. medRxiv (2020): doi:10.1101/2020.06.26.20141341.
‘Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity’
Ausar, S.F. et al. Communications Biology 3 (2020): 427.
‘A human circulating immune cell landscape in aging and COVID-19’
Zheng, Y. et al. Protein Cell (2020): doi:10.1007/s13238-020-00762-2.
‘Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity’
Vanderbeke, L. et al. Research Square (2020):doi:0.21203/rs.3.rs-60579/v1.
Use of the assay in clinical trials
A multi-institutional collaborative study in the United Kingdom is using the Maxpar Direct Immune Profiling Assay for participant immunomonitoring in a clinical trial for major depressive disorder.
Patients who have not responded to conventional antidepressant drugs will be treated with an anti-inflammatory drug to reduce stress-related depression. The assay will be used to assess changes in peripheral blood at baseline and after eight weeks of daily treatment.
Lori Turner, a researcher at the University of Cambridge, explains why her team selected the Maxpar Direct Immune Profiling System for standardized immune profiling in this clinical study.
Read the interview
Complete the form below to talk to a Field Applications Specialist about panel design for my unique research project or to learn more about the Maxpar Direct Immune Profiling System.
For Research Use Only. Not for use in diagnostic procedures.